Target intelligence / Profile preview

Cyclic nucleotide-gated channel subunit alpha 1 (CNGA1)

Target
CNGA1
Molecular classification
Ion channel, Cyclic nucleotide-regulated channel, Ligand-gated ion channel, Pore-forming subunit
01

Overview

Cyclic nucleotide-gated channel subunit alpha 1 (CNGA1) is a pore-forming subunit of the rod photoreceptor cGMP-gated ion channel, essential for the phototransduction cascade in vertebrate vision[1][2]. CNGA1 combines with beta subunits (sometimes CNGB1) to form the functional cGMP-gated cation channel of rod photoreceptors. When darkness prevails, high intracellular cGMP concentrations keep the channel open, enabling a steady influx of Na⁺ and Ca²⁺, which maintains the resting depolarized state required for neurotransmitter release. Upon light activation, cGMP concentrations decrease, closing the channel, resulting in membrane hyperpolarization and visual signal transmission. Structural studies reveal that CNGA1 has a six-transmembrane domain topology, shares similarities to voltage-gated channels while being directly regulated by cyclic nucleotides, and features unique Ca²⁺ binding/interaction mechanisms[1]. Loss-of-function mutations in CNGA1 lead to autosomal recessive retinitis pigmentosa by disrupting normal phototransduction[2].

Other names
Cyclic nucleotide-gated channel alpha-1CNG channel alpha-1CNG-1CNG1CNCG1CNCGRod photoreceptor cGMP-gated channel subunit alphacGMP-gated cation channel alpha-1Cyclic nucleotide-gated cation channel 1Cyclic nucleotide-gated channel, photoreceptorRCNCalphaRCNC1RCNCaRP49Interleukin-1 homologue
02

Mechanism of action

Ligand binding (cGMP > cAMP) leads to channel opening, allowing influx of cations (primarily Na⁺ and Ca²⁺) Channel gating and ion selectivity determine photoreceptor depolarization/hyperpolarization in response to light[1][3]

03

Biological functions

Signal transductionPhototransductionVisual sensory signalingCation transportConversion of cGMP signals into electrical responses in rods
04

Disease associations

Retinal diseases (notably Retinitis pigmentosa)Other inherited retinal degenerations
05

Safety considerations

Vision loss due to channel dysfunction (primarily in context of inherited disorders, e.g., mutations causing retinitis pigmentosa)Not a major drug safety concern as no approved drugs directly target CNGA1
06

Interacting drugs

No established approved drugs directly targeting CNGA1 for therapeutic use

1 more in the full profile.

07

Biomarkers

Mutational analysis of CNGA1 (genetic testing) is used as a biomarker in diagnosis and prognosis of retinitis pigmentosa and related hereditary retinal diseases[2]

Beyond the preview

Go deeper on Cyclic nucleotide-gated channel subunit alpha 1 (CNGA1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclic nucleotide-gated channel subunit alpha 1 (CNGA1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call